GMABGENMAB A/S同业对比
GENMAB A/S 与iShares Biotechnology ETF 持仓的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:IBB 前十大持仓| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GMAB本股 | — | — | — | — | 19.2%#7 | -15.0%#12 | 28.6%#6 | — | — | — | 23.0%#12 | — |
| VRTX | $130.9B#4 | 30.1x#5 | 6.5x#3 | 10.9x#7 | 8.9%#9 | 838.1%#3 | 34.8%#2 | 19.5%#6 | 25.0%#5 | — | 33.5%#11 | — |
| AMGN | $205.3B#2 | 23.6x#4 | 17.6x#8 | 5.6x#3 | 10.0%#8 | 88.5%#7 | 24.7%#8 | 66.0%#2 | 15.1%#7 | — | 41.7%#7 | 2.5%#1 |
| GILD | $187.2B#3 | — | 15.8x#6 | 6.4x#4 | 2.4%#10 | 1672.9%#2 | 34.0%#3 | 71.9%#1 | 26.7%#4 | — | 37.3%#8 | 2.1%#2 |
| REGN | — | 19.5x#2 | — | — | 1.0%#12 | 2.1%#10 | 24.9%#7 | 14.2%#7 | 9.4%#9 | — | 34.8%#10 | — |
| ARGX | $61.6B#6 | — | — | 1734.2x#12 | 254.4%#1 | 55.1%#8 | 2965.7%#1 | — | — | — | 35.7%#9 | — |
| ALNY | $32.8B#10 | 42.8x#6 | 24.3x#9 | 8.8x#6 | 65.2%#3 | 212.8%#4 | 13.5%#10 | 23.2%#4 | 150.5%#1 | — | -45.6%#15 | — |
| NTRA | $52.8B#7 | — | 29.0x#10 | 22.9x#8 | 35.9%#5 | -9.3%#11 | -13.4%#12 | -11.4%#10 | -18.0%#10 | — | 108.7%#4 | — |
| RVMD | $42.2B#8 | — | 16.2x#7 | — | — | -88.5%#15 | — | -43.4%#12 | — | — | 349.4%#2 | — |
| BIIB | $32.3B#11 | 23.6x#3 | 2.2x#1 | 3.3x#1 | 2.2%#11 | -20.8%#13 | 28.7%#5 | 8.7%#8 | 13.0%#8 | 4#3 | 51.2%#5 | — |
| ILMN | $37.0B#9 | 45.8x#7 | 13.1x#5 | 8.5x#5 | -0.7%#13 | 169.5%#5 | 18.6%#9 | 30.0%#3 | 22.0%#6 | 7#1 | 143.1%#3 | — |
| MRNA | $63.1B#5 | — | 9.3x#4 | 32.5x#9 | -39.9%#14 | 20.8%#9 | -158.1%#13 | -41.7%#11 | -54.6%#11 | — | 531.8%#1 | — |
| INSM | $27.1B#12 | — | 35.8x#11 | 44.7x#10 | 66.7%#2 | -39.7%#14 | -205.6%#14 | -168.6%#13 | -163.0%#12 | 3#4 | -14.3%#14 | — |
| ONC | $522.5B#1 | 822.1x#8 | 101.0x#12 | 97.8x#11 | 40.2%#4 | 144.5%#6 | 8.4%#11 | 5.5%#9 | 29.9%#3 | 6#2 | 6.2%#13 | — |
| INCY | $25.5B#13 | 18.0x#1 | 4.5x#2 | 5.0x#2 | 21.2%#6 | 3846.9%#1 | 29.5%#4 | 22.9%#5 | 49.0%#2 | — | 50.5%#6 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议